MAGEA3 MAGE family member A3
ENSG00000221867 · protein coding · Open Targets profile
Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a repressor of autophagy (PubMed:20864041, PubMed:31267705). May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex (PubMed:17942928, PubMed:20864041). May play a role in embryonal development and tumor transformation or aspects of tumor progression (PubMed:17942928, PubMed:20864041). In vitro promotes cell viability in melanoma cell lines (PubMed:17942928). Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes (PubMed:8113684). {ECO:0000269|PubMed:17942928, ECO:0000269|PubMed:20864041, ECO:0000269|PubMed:31267705, ECO:0000269|PubMed:8113684}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand
- PROTAC
- UniProt Ubiquitination, Database Ubiquitination
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e – (upper bound –). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 6 registry trials, updated in the last three years, of the most advanced drugs against MAGEA3 (astuprotimut-r, biropepimut-s), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Derek JonkerOttawa Hospital Research Institute · 1 of 1 trials Phase 2+
- Fiona BlackhallThe Christie NHS Foundation Trust · 1 of 1 trials Phase 2+
- Johan VansteenkisteKU Leuven · 1 of 1 trials Phase 2+
- David ChungMemorial Sloan Kettering Cancer Center · 0 of 1 trials Phase 2+
Registry trials of astuprotimut-r, biropepimut-s updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 4 of 6 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.
15 trials of drugs against MAGEA3 were stopped early; 2 give no reason
Terminated, withdrawn and suspended interventional trials of astuprotimut-r, biropepimut-s, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 15 most recent of 15.
- suspended · 2026-04-06 · Cancer Research UK · matched by the registry's drug synonyms“Sponsor has decided to permanently close recruitment”
- terminated · 2023-08-25 · Kite, A Gilead Company · matched by the registry's drug synonyms“The study was terminated due to the sponsor's decision to discontinue the clinical trial.”
- withdrawn · 2021-04-06 · Turnstone Biologics, Corp. · matched by the registry's drug synonyms“insufficient suitable drug supply”
- terminated · 2021-03-05 · GlaxoSmithKline · matched by the registry's drug synonyms“The study was terminated early following assessment of the two co-primary endpoints showing the lack of efficacy of the study product.”
- terminated · 2020-12-22 · GlaxoSmithKline · matched by the registry's drug synonyms“The study was terminated following assessment of the lack of efficacy of the study product by the Independent Data monitoring Committee for the study.”
- terminated · 2020-10-08 · GlaxoSmithKline · matched by the registry's drug synonyms“The study was terminated early due to difficulties in recruiting subjects, not following concerns for the safety or absence of clinical activity in patients.”
- terminated · 2020-06-11 · Centre Hospitalier Universitaire Vaudois · matched by the registry's drug synonyms“Low enrollment rate”
- terminated · 2019-12-20 · H. Lee Moffitt Cancer Center and Research Institute · matched by the registry's drug synonyms“Treatment Ineffective”
- terminated · 2019-06-17 · National Cancer Institute (NCI) · matched by the registry's drug synonyms“Slow, insufficient accrual.”
- terminated · 2019-01-09 · European Association of Urology Research Foundation · matched by the registry's drug synonymsNo reason given
- withdrawn · 2017-11-24 · Penn State University · matched by the registry's drug synonyms“unexpectedly low screening results leading to poor accrual”
- terminated · 2017-07-12 · GlaxoSmithKline · matched by the registry's drug synonyms“Early end of trial notification after termination of long term follow up due to lack of scientific justification to continue collect information.”
- terminated · 2017-05-15 · GlaxoSmithKline · matched by the registry's drug synonyms“Study early termination was due to slow recruitment and difficulties at achieving the required enrolment for the study.”
- withdrawn · 2017-05-09 · University of Louisville · matched by the registry's drug synonyms“Adult patient population barriers.”
- terminated · 2015-10-28 · National Cancer Institute (NCI) · matched by the registry's drug synonymsNo reason given
Paediatric incentives and obligations for MAGEA3's drugs
For astuprotimut-r, biropepimut-s: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: yes · MAGEA3 is on the list. Membership alone neither requires nor waives a pediatric study.Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names astuprotimut-r, biropepimut-sRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names astuprotimut-r, biropepimut-sRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of astuprotimut-r, biropepimut-sRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of astuprotimut-r, biropepimut-sRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 1 interventional studies of astuprotimut-r, biropepimut-s include patients under 18; 0 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 2 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| ASTUPROTIMUT-R | Unknown | phase 3 | non-small cell lung carcinoma, plasma cell myeloma, melanoma, head and neck squamous cell carcinoma | Open Targets · ChEMBL |
| BIROPEPIMUT-S | Unknown | phase 2 | head and neck cancer, plasma cell myeloma, oral cavity squamous cell carcinoma, squamous cell carcinoma | Open Targets · ChEMBL |